Table 4.
One-year univariate survival analysis.
| Variable | Categories | Events/N | HR (95% CI) | p-value | 1-year survival |
|---|---|---|---|---|---|
| Sex | Female | 5/25 | 1.00 | 0.5 | 80 (58–91) |
| Male | 10/34 | 1.49 (0.51–4.35) | 69 (50–82) | ||
| Race | White | 14/53 | 1.00 | 0.7 | 71 (57–83) |
| Black | 1/5 | 0.68 (0.09–5.14) | 80 (20–97) | ||
| AL subtype | Lambda | 10/46 | 1.00 | 0.1 | 77 (62–87) |
| Kappa | 5/13 | 2.36 (0.80–6.92) | 60 (28–81) | ||
| 2004 stage | I-II | 2/31 | 1.00 | 0.002 | 93 (76–98) |
| IIIa | 7/18 | 7.24 (1.50–34.88) | 0.01 | 60 (34–79) | |
| IIIb | 6/8 | 17.46 (3.51–86.88) | 0.0005 | 25 (4–56) | |
| Stage 2012 | 1–2 | 1/27 | 1.00 | 0.002 | 96 (76–99) |
| 3 | 7/20 | 10.58 (1.30–86.03) | 0.03 | 62.5 (36–80) | |
| 4 | 7/10 | 33.42 (4.09–273.25) | 0.001 | 30 (7–58) | |
| Cardiac AL | No | 0/20 | 100 | ||
| Yes | 15/39 | NE | NE | 59 (42–73) | |
| Renal AL | No | 6/25 | 1.00 | 0.9 | 76 (54–88) |
| Yes | 9/34 | 1.07 (0.38–3.00) | 71 (52–84) | ||
| Number of organs involved | 1 | 3/21 | 1.00 | 0.02 | 86 (62–95) |
| 2 | 4/23 | 1.24 (0.27–5.57) | 0.8 | 81 (55–92) | |
| 3/+ | 8/15 | 5.03 (1.32–19.24) | 0.02 | 39 (12–66) |
NE non-evaluable.